Safety and Efficacy of Periprocedural Apixaban Use for Reduction of the Risk of Cerebrovascular Events in Patients Undergoing Ventricular Tachycardia Radiofrequency Catheter Ablation
Safety and Efficacy of Periprocedural Apixaban Use for Reduction of the Risk of Cerebrovascular Events in Patients Undergoing Ventricular Tachycardia Radiofrequency Catheter Ablation
The purpose of this study is to learn if taking a drug called Apixaban after an ablation
 procedure keeps blood clots from forming and lowers the chance of having a stroke in patients
 with ventricular tachycardia (VT).
Ventricular tachycardia (VT) or fast heart rhythm is a condition where the lower chambers
 (ventricles) of the heart beat too fast. This condition can be life threatening because these
 ventricles are the main pumping chambers of the heart. The fast heartbeat is caused by
 electrical impulses that travel incorrectly in your heart.

 One way to treat VT is to have a catheter ablation procedure. A catheter ablation is a
 procedure that creates scar tissue in the heart to interrupt the electrical impulses that
 create irregular heart rhythms.

 It is possible that the ablation procedure might cause a blood clot to form. The blood clot
 can stop blood flow to the brain and cause a stroke. When blood flow is interrupted to a
 certain part of the brain, that part does not receive enough oxygen. As a result of the
 stroke the affected areas of the brain are unable to function normally.

 Apixaban (also known as Eliquis) is a blood thinning drug, also called an anticoagulant. It
 interferes with the body's natural blood clotting ability by inactivating a specific enzyme
 that the body needs to form blood clots.

 Participation in this study will last about 30 days.
Inclusion Criteria:

 -  Patients undergoing radiofrequency catheter ablation for scar VT which includes VT
 secondary to ischemic cardiomyopathy and non-ischemic cardiomyopathy

 -  Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy
 test within 24 hours prior to the start of study drug

 -  Women must not be breastfeeding

 -  WOCBP must agree to follow instructions for method(s) of contraception for the
 duration of treatment with Apixaban plus 33 days post-treatment completion

 -  Males who are sexually active with WOCBP must agree to follow instructions for
 method(s) of contraception for the duration of treatment and for a total of 93 days
 post-treatment completion

 -  Participants must agree to the use of one approved method of contraception

 Exclusion Criteria:

 -  History of cerebral vascular accident/transient ischemic attack (CVA/TIA) in last 3
 months

 -  Cardiac surgery or neurosurgery within 3 months of the intended procedure date

 -  Any active bleeding

 -  Severe hypersensitivity reaction to ELIQUIS (including drug hypersensitivity, such as
 skin rash and allergic reactions)

 -  Participants cannot have prosthetic heart valves

 -  History or bleeding and clotting disorders

 -  Contraindications to Aspirin therapy

 -  Contraindication to oral anticoagulation

 -  Patient on an anticoagulant prior to the ablation for other primary indications like
 atrial fibrillation (AF), deep vein thrombosis (DVT) or a mechanical valve

 -  Evidence of intracardiac thrombus

 -  Patient with Creatinine Clearance of < 30 cc/min

 -  Participation in another investigational study related to oral anticoagulation, drug
 and/or device intervention

 -  Claustrophobic patients

 -  Implantable Cardioverter Defibrillator (ICD) generator placement before the year 2000

 -  Has an ICD and is pacing dependent without underlying rhythm upon interrogation at
 baseline

 -  Patient has abandoned leads

 -  Patients who are on p-glycoprotein inducers or inhibitors where the dose of Apixaban
 cannot be effectively altered